Q2054 Lisocabtagene mara car pos t
Also known as: Jcar017, lisocabtagene maraleucel, CAR-T
Lisocabtagene maraleucel CAR-T cell immunotherapy for CD19-positive B-cell lymphomas.
In Plain Language
cancer cell fighter; engineered cell therapy
Clinical Context
Used for relapsed/refractory large B-cell lymphoma. Engineered CAR-T cells target CD19+ cells. Requires inpatient monitoring for immune effects.
RVU Information
CPT Q2054 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2054?
CPT Q2054 (Lisocabtagene mara car pos t) is a Q Codes code. Lisocabtagene maraleucel CAR-T cell immunotherapy for CD19-positive B-cell lymphomas.
Is Q2054 covered by insurance?
Q2054 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for relapsed/refractory large B-cell lymphoma. Engineered CAR-T cells target CD19+ cells. Requires inpatient monitoring for immune effects.
When is CPT Q2054 used?
Used for relapsed/refractory large B-cell lymphoma. Engineered CAR-T cells target CD19+ cells. Requires inpatient monitoring for immune effects.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.